Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Earnings for Tiziana Life Sciences Ltd (TLSA)
Earnings in 2022 (TTM): $-15,397,000
According to Tiziana Life Sciences Ltd's latest financial reports the company's current earnings (TTM) are $-15,397,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Tiziana Life Sciences Ltd
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-15,397,000 | $-16,208,000 |
| 2021 | $-26,657,000 | $-23,417,000 |
| 2020 | $-30,073,456 | $-27,730,760 |
| 2019 | $-10,287,408 | $-9,579,378 |
| 2018 | $-9,458,431 | $-7,607,096 |
| 2017 | $-11,155,858 | $-9,149,020 |
| 2016 | $-9,003,085 | $-8,893,276 |
| 2015 | $-12,788,338 | $-12,788,338 |
| 2014 | $-5,556,593 | $-5,463,205 |
| 2013 | $-466,666 | $-466,666 |
| 2012 | $-1,055,251 | $-1,055,251 |
| 2011 | $-448,702 | $-1,207,924 |
| 2010 | $ | $-4,678,047 |
| 2009 | $-1,225,684 | $-1,180,408 |
| 2008 | $-2,211,255 | $-2,142,428 |
| 2007 | $-5,128,409 | $-4,729,797 |
| 2006 | $-4,494,426 | $-4,263,239 |
| 2005 | $-3,825,108 | $-3,684,011 |
| 2004 | $-2,880,927 | $-2,662,268 |
| 2003 | $-3,557,143 | $-3,503,571 |
| 2002 | $-3,818,958 | $-3,715,873 |
| 2001 | $-3,507,548 | $-3,378,231 |
| 2000 | $-3,511,471 | $-3,387,501 |
| 1999 | $-896,208 | $-896,208 |
| 1998 | $-451,490 | $-451,490 |